Synthesis and anti-endoplasmic reticulum stress activity of N-substituted-2-arylcarbonylhydrazinecarbothioamides

Misfolded or unfolded proteins are accumulated in lumen of endoplasmic reticulum (ER) in ER stress condition. It has been implicated in many pathological conditions such as Alzheimer’s disease, diabetic retinopathy, atherosclerosis, β-cell apoptosis and lung inflammation. We found a series of N -sub...

Full description

Saved in:
Bibliographic Details
Published inMedicinal chemistry research Vol. 28; no. 12; pp. 2142 - 2152
Main Authors Choi, Hoon, Yun, Wheesahng, Lee, Jung-hun, Jang, Seoul, Park, Sang Won, Kim, Dong Hwan, Seon, Kyoung Pyo, Hyun, Jung-mi, Jeong, Kwiwan, Ku, Jin-mo, Nam, Tae-gyu
Format Journal Article
LanguageEnglish
Published New York Springer US 01.12.2019
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Misfolded or unfolded proteins are accumulated in lumen of endoplasmic reticulum (ER) in ER stress condition. It has been implicated in many pathological conditions such as Alzheimer’s disease, diabetic retinopathy, atherosclerosis, β-cell apoptosis and lung inflammation. We found a series of N -substituted-2-arylcarbonylhydrazinecarbothioamides to potently decrease ER stress signal, showing up to almost 300-fold better activity than 1-hydroxynaphthoic acid and tauro-ursodesoxycholic acid, positive controls, respectively. Structure−activity relationship (SAR) study showed that 2-arylcarbonyl moiety is critical for the activity of the hydrazinecarbothioamide analogues and side chains tethering on thioamide moiety were relatively insensitive to the activity. Some analogues were found to consistently exert the potency under more physiologically relevant condition where ER stress was induced by palmitic acid. ER stress markers such as CHOP and phosphorylated eIF2α and PERK were accordingly decreased in western blotting upon treatment of compound 4h . Potential ER stress inhibitory activity and novel structures could provide a novel platform for new chemical chaperone and therapy for protein misfolding diseases.
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-019-02442-1